New Prostate Cancer Treatment Options

New Prostate Cancer Treatment Options

Approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime (often occurring later in life). “As patients tend to be older and sicker, there is a need to find effective treatments with milder side effects that don’t affect the patient’s quality of life.” Prostate cancer is the second leading cause of death in men in the United States. There is a need for improved treatment options.

New Treatments In 2025-2026

An estimated 6 in 10 prostate cancers are diagnosed in men who are 65 years or older. 

New prostate cancer treatment options are imaging, targeted therapies, medication combinations, and precision medicine. 

IMAGING

A PSMA PET scan is an advanced and highly accurate imaging test that uses a radioactive tracer to detect prostate cancer cells throughout the body. It targets the Prostate-Specific-Membrane Antigen (PSMA) protein that is found on cancer cells. This makes it a superior test to help detect recurring or spread (metastatic) cancer.

• This test determines if newly diagnosed prostate cancer is confined to the prostate or has spread elsewhere.

• This test can help find cancer cells when PSA levels (prostate-specific antigen) rise after treatments such as surgery or radiation.

• This can help doctors make informed decisions concerning targeted therapies.

• This scan is considered a game-changer for its ability to guide precision care.

The process for this scan can be mapped within several hours. A radioactive tracer is injected into a vein and then binds to PSMA-positive cancer cells. A PET scanner maps out the tracer’s locations. This is usually about an hour after injection. This process provides a higher accuracy than a traditional CT or bone scan in accurately finding small, metastatic tumor spots.

TARGETED THERAPIES

Pluvicto is an FDA-approved targeted radiation treatment for patients with PSMA-positive metastatic (castration-resistant) prostate cancer that has spread and has already been treated with other therapies. It is not chemotherapy; it is a treatment called radioligand therapy (RLT).

Pluvicto is designed to locate and attack PSMA-positive cells. PSMA is found on most prostate cancer cells and some healthy cells. Once Pluvicto is absorbed into the cancer cell, it releases radiation, which destroys the cell from the inside. It is given by IV infusion every 6 weeks for 6 cycles. 

Other Key Targeted Therapies:

• PARP Inhibitors: These medications block a protein called PARP that repairs DNA. This causes the cancer cells with a genetic mutation to die.

• Olaparib (Lynparza), Talazoparib (Talzenna), Rucaparib (Rubraca)

• Targeted Radiopharmaceuticals: Radium 223 dichloride (Xofigo) binds with bone metastases to kill cancer cells. This is often used when cancer has spread to the bones.

• Hormone Combination Therapies: Akeega (Niraparib + Abiraterone), Abiraterone acetate (Zytiga), Enzalutamide (Xtandi), Apalutamide (Erleada), Darolutamide (Nubeqa), Relugolix (Orgovyx).

PRECISION MEDICINE

This is a personalized approach using the patient’s genetic testing, molecular imaging, and tumor profiling data to create a specific, tailored diagnosis and treatment. This attacks genetic alterations in the tumor and improves outcomes by using treatments that precisely aim for the patient’s unique cancer biology.

• Immunotherapy: Sipuleucel-T (Provenge) is the first FDA-approved immunotherapy designed to treat advanced prostate cancer that is no longer responding to hormone therapy. It works by collecting a patient’s own immune cells and modifying them to attack cancer cells. The process involves 3 infusions, each spaced 2 weeks apart. 

• Targeted Immunotherapy: Pembrolizumab (Keytruda) is used to treat tumors with specific markers such as microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), which means the cancer has a high number of mutations.

Conclusion

The landscape of prostate cancer is changing rapidly, which offers hope for patients through advanced imaging, targeted therapies, and precision medicine. New advancements aim to extend survival and prioritize quality of life. As research continues, the future of prostate cancer treatment looks promising.